Thêta-Cream versus Bepanthol lotion in breast cancer patients under radiotherapy. A new prophylactic agent in skin care?

Röper B, Kaisig D, Auer F, Mergen E, Molls M

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]1 May 2004Cited by 27 (Europe PMC)

PMID15127162DOI10.1007/s00066-004-1174-9PepBankPUB-15127162

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone11

In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Matrixyl (palmitoyl pentapeptide-4).

01HumanNot a test of Matrixyl (palmitoyl pentapeptide-4) aloneRandomized controlled trialSafety outcome
In breast cancer patients receiving radiotherapy, combination Thêta-Cream showed no difference in acute skin toxicity scores versus Bepanthol lotion.
In plain wordsIn breast cancer patients receiving radiotherapy, the combination cream and Bepanthol had similar skin toxicity scores.
Peptide
Matrixyl (palmitoyl pentapeptide-4)
Outcome
No significant changeAcute skin toxicity scores
Study
n = 20
Comparator
Bepanthol lotion
Outcome group
Adverse events · Skin and wound
Source sentences
Summary
For single aspects of toxicity and their sums in defined skin areas, no differences in median and range between study groups were found.
2 context sentences(design, population, supporting numbers)
Summary · context
After phase II studies, Thêta-Cream, containing CM Glucan, Hydroxyprolisilan C und Matrixyl as active substances, was said to have prophylactic properties of preventing acute radiation side effects in skin tissue.
Summary · context
20 breast cancer patients were randomly assigned to use Thêta-Cream or Bepanthol lotion during radiotherapy.
In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Matrixyl (palmitoyl pentapeptide-4).
Report a problemFND-1512716201
02HumanNot a test of Matrixyl (palmitoyl pentapeptide-4) aloneRandomized controlled trialSafety outcome
In breast cancer patients receiving radiotherapy, maximal toxicity averaged moderate erythema with both Thêta-Cream and Bepanthol.
In plain wordsIn breast cancer patients receiving radiotherapy, both the combination cream and Bepanthol groups had moderate skin redness.
Peptide
Matrixyl (palmitoyl pentapeptide-4)
Outcome
No significant changeErythema
Study
n = 20
Comparator
Bepanthol lotion
Outcome group
Adverse events · Skin and wound
Source sentences
Summary
The maximal toxicity anywhere in the breast averaged in a moderate erythema, mild elevation of skin temperature, no desquamation in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
After phase II studies, Thêta-Cream, containing CM Glucan, Hydroxyprolisilan C und Matrixyl as active substances, was said to have prophylactic properties of preventing acute radiation side effects in skin tissue.
Summary · context
20 breast cancer patients were randomly assigned to use Thêta-Cream or Bepanthol lotion during radiotherapy.
In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Matrixyl (palmitoyl pentapeptide-4).
Report a problemFND-1512716202
03HumanNot a test of Matrixyl (palmitoyl pentapeptide-4) aloneRandomized controlled trialSafety outcome
In breast cancer patients receiving radiotherapy, mild skin temperature elevation occurred with both Thêta-Cream and Bepanthol.
In plain wordsIn breast cancer patients receiving radiotherapy, both the combination cream and Bepanthol groups had mildly increased skin temperature.
Peptide
Matrixyl (palmitoyl pentapeptide-4)
Outcome
No significant changeSkin temperature elevation
Study
n = 20
Comparator
Bepanthol lotion
Outcome group
Adverse events · Skin and wound
Source sentences
Summary
The maximal toxicity anywhere in the breast averaged in a moderate erythema, mild elevation of skin temperature, no desquamation in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
After phase II studies, Thêta-Cream, containing CM Glucan, Hydroxyprolisilan C und Matrixyl as active substances, was said to have prophylactic properties of preventing acute radiation side effects in skin tissue.
Summary · context
20 breast cancer patients were randomly assigned to use Thêta-Cream or Bepanthol lotion during radiotherapy.
In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Matrixyl (palmitoyl pentapeptide-4).
Report a problemFND-1512716203
04HumanNot a test of Matrixyl (palmitoyl pentapeptide-4) aloneRandomized controlled trialSafety outcome
In breast cancer patients receiving radiotherapy, neither Thêta-Cream nor Bepanthol groups showed desquamation.
In plain wordsIn breast cancer patients receiving radiotherapy, neither the combination cream nor Bepanthol group had skin peeling.
Peptide
Matrixyl (palmitoyl pentapeptide-4)
Outcome
No significant changeDesquamation
Study
n = 20
Comparator
Bepanthol lotion
Outcome group
Adverse events · Skin and wound
Source sentences
Summary
The maximal toxicity anywhere in the breast averaged in a moderate erythema, mild elevation of skin temperature, no desquamation in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
After phase II studies, Thêta-Cream, containing CM Glucan, Hydroxyprolisilan C und Matrixyl as active substances, was said to have prophylactic properties of preventing acute radiation side effects in skin tissue.
Summary · context
20 breast cancer patients were randomly assigned to use Thêta-Cream or Bepanthol lotion during radiotherapy.
In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Matrixyl (palmitoyl pentapeptide-4).
Report a problemFND-1512716204
05HumanNot a test of Matrixyl (palmitoyl pentapeptide-4) aloneRandomized controlled trialSafety outcome
In breast cancer patients receiving radiotherapy, mild itchiness was more frequent with Thêta-Cream than Bepanthol.
In plain wordsIn breast cancer patients receiving radiotherapy, mild itching was more common with the combination cream than Bepanthol.
Peptide
Matrixyl (palmitoyl pentapeptide-4)
Outcome
IncreaseItchiness
Study
n = 20
Comparator
Bepanthol lotion
Outcome group
Adverse events · Skin and wound
Source sentences
Summary
Mild itchiness and sporadic efflorescences were more frequently seen with Thêta-Cream.
2 context sentences(design, population, supporting numbers)
Summary · context
After phase II studies, Thêta-Cream, containing CM Glucan, Hydroxyprolisilan C und Matrixyl as active substances, was said to have prophylactic properties of preventing acute radiation side effects in skin tissue.
Summary · context
20 breast cancer patients were randomly assigned to use Thêta-Cream or Bepanthol lotion during radiotherapy.
In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Matrixyl (palmitoyl pentapeptide-4).
Report a problemFND-1512716205
06HumanNot a test of Matrixyl (palmitoyl pentapeptide-4) aloneRandomized controlled trialSafety outcome
In breast cancer patients receiving radiotherapy, sporadic efflorescences were more frequent with Thêta-Cream than Bepanthol.
In plain wordsIn breast cancer patients receiving radiotherapy, occasional skin eruptions were more common with the combination cream than Bepanthol.
Peptide
Matrixyl (palmitoyl pentapeptide-4)
Outcome
IncreaseEfflorescences
Study
n = 20
Comparator
Bepanthol lotion
Outcome group
Adverse events · Skin and wound
Source sentences
Summary
Mild itchiness and sporadic efflorescences were more frequently seen with Thêta-Cream.
2 context sentences(design, population, supporting numbers)
Summary · context
After phase II studies, Thêta-Cream, containing CM Glucan, Hydroxyprolisilan C und Matrixyl as active substances, was said to have prophylactic properties of preventing acute radiation side effects in skin tissue.
Summary · context
20 breast cancer patients were randomly assigned to use Thêta-Cream or Bepanthol lotion during radiotherapy.
In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Matrixyl (palmitoyl pentapeptide-4).
Report a problemFND-1512716206
07HumanNot a test of Matrixyl (palmitoyl pentapeptide-4) aloneRandomized controlled trialSafety outcome
In breast cancer patients receiving radiotherapy, independent photographic rankings showed equal side effects with Thêta-Cream and Bepanthol.
In plain wordsIn breast cancer patients receiving radiotherapy, independent photo ratings showed equal side effects with the combination cream and Bepanthol.
Peptide
Matrixyl (palmitoyl pentapeptide-4)
Outcome
No significant changePhotographic side effect ranking
Study
n = 20
Comparator
Bepanthol lotion
Outcome group
Adverse events · Skin and wound
Source sentences
Summary
According to a ranking of anonymized breast photos at 50 Gy by independent investigators, side effects were equal.
2 context sentences(design, population, supporting numbers)
Summary · context
After phase II studies, Thêta-Cream, containing CM Glucan, Hydroxyprolisilan C und Matrixyl as active substances, was said to have prophylactic properties of preventing acute radiation side effects in skin tissue.
Summary · context
20 breast cancer patients were randomly assigned to use Thêta-Cream or Bepanthol lotion during radiotherapy.
In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Matrixyl (palmitoyl pentapeptide-4).
Report a problemFND-1512716207
08HumanNot a test of Matrixyl (palmitoyl pentapeptide-4) aloneRandomized controlled trialOther
In breast cancer patients receiving radiotherapy, satisfaction was high with both Thêta-Cream and Bepanthol.
In plain wordsIn breast cancer patients receiving radiotherapy, satisfaction was high with both the combination cream and Bepanthol.
Peptide
Matrixyl (palmitoyl pentapeptide-4)
Outcome
Not applicablePatient satisfaction
Study
n = 20
Comparator
Bepanthol lotion
Outcome group
Patient-reported outcomes · Skin and wound
Measurements
Patient satisfaction
1.25 score
both regimens, scale 0 to 10
Source sentences
Summary
Patients' content was high with both skin care regimens (1.25 on a scale from 0 to 10).
2 context sentences(design, population, supporting numbers)
Summary · context
After phase II studies, Thêta-Cream, containing CM Glucan, Hydroxyprolisilan C und Matrixyl as active substances, was said to have prophylactic properties of preventing acute radiation side effects in skin tissue.
Summary · context
20 breast cancer patients were randomly assigned to use Thêta-Cream or Bepanthol lotion during radiotherapy.
In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Matrixyl (palmitoyl pentapeptide-4).
Report a problemFND-1512716208
09HumanNot a test of Matrixyl (palmitoyl pentapeptide-4) aloneRandomized controlled trialOther
In breast cancer patients receiving radiotherapy, Thêta-Cream showed a trend toward worse skin marks than Bepanthol.
In plain wordsIn breast cancer patients receiving radiotherapy, skin marks tended to be worse with the combination cream than Bepanthol.
Peptide
Matrixyl (palmitoyl pentapeptide-4)
Outcome
DecreaseTechnical assistants' content with skin marks
Study
n = 20
Comparator
Bepanthol lotion
Outcome group
Adverse events · Skin and wound
Source sentences
Summary
With Thêta-Cream a trend toward worse skin marks was noted.
2 context sentences(design, population, supporting numbers)
Summary · context
After phase II studies, Thêta-Cream, containing CM Glucan, Hydroxyprolisilan C und Matrixyl as active substances, was said to have prophylactic properties of preventing acute radiation side effects in skin tissue.
Summary · context
20 breast cancer patients were randomly assigned to use Thêta-Cream or Bepanthol lotion during radiotherapy.
In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Matrixyl (palmitoyl pentapeptide-4).
Report a problemFND-1512716209
10HumanNot a test of Matrixyl (palmitoyl pentapeptide-4) aloneRandomized controlled trialSafety outcome
In breast cancer patients receiving radiotherapy, one suspected allergic reaction occurred exclusively among Thêta-Cream users.
In plain wordsIn breast cancer patients receiving radiotherapy, a suspected allergic reaction occurred only with the combination cream.
Peptide
Matrixyl (palmitoyl pentapeptide-4)
Outcome
IncreaseSuspected allergic reaction
Study
n = 20
Comparator
Bepanthol lotion
Outcome group
Adverse events · Skin and wound
Source sentences
Summary
Adverse events exclusively occurred in Thêta-Cream users: suspected allergic reaction once, and the necessity for resimulation twice.
2 context sentences(design, population, supporting numbers)
Summary · context
After phase II studies, Thêta-Cream, containing CM Glucan, Hydroxyprolisilan C und Matrixyl as active substances, was said to have prophylactic properties of preventing acute radiation side effects in skin tissue.
Summary · context
20 breast cancer patients were randomly assigned to use Thêta-Cream or Bepanthol lotion during radiotherapy.
In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Matrixyl (palmitoyl pentapeptide-4).
Report a problemFND-1512716210
11HumanNot a test of Matrixyl (palmitoyl pentapeptide-4) aloneRandomized controlled trialSafety outcome
In breast cancer patients receiving radiotherapy, resimulation was necessary twice exclusively among Thêta-Cream users.
In plain wordsIn breast cancer patients receiving radiotherapy, repeat simulation was necessary only with the combination cream.
Peptide
Matrixyl (palmitoyl pentapeptide-4)
Outcome
IncreaseResimulation requirement
Study
n = 20
Comparator
Bepanthol lotion
Outcome group
Adverse events · Skin and wound
Source sentences
Summary
Adverse events exclusively occurred in Thêta-Cream users: suspected allergic reaction once, and the necessity for resimulation twice.
2 context sentences(design, population, supporting numbers)
Summary · context
After phase II studies, Thêta-Cream, containing CM Glucan, Hydroxyprolisilan C und Matrixyl as active substances, was said to have prophylactic properties of preventing acute radiation side effects in skin tissue.
Summary · context
20 breast cancer patients were randomly assigned to use Thêta-Cream or Bepanthol lotion during radiotherapy.
In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Matrixyl (palmitoyl pentapeptide-4).
Report a problemFND-1512716211

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.